Epirubicin/Taxane Combinations in Breast Cancer: Experience From Several Italian Trials
May 1st 2001Doxorubicin/paclitaxel (Taxol) combinations are very active in advanced breast cancer, with objective response rates up to 90%, but have shown a high incidence of cardiotoxicity. A phase I/II trial replacing
Gemcitabine/Epirubicin/Paclitaxel Trials in Advanced Breast Cancer
February 1st 2001Numerous trials have shown that the pharmacokinetic interferences of epirubicin (Ellence)/paclitaxel (Taxol) combinations produce less pharmacodynamic effect than doxorubicin/paclitaxel regimens. Paclitaxel is more easily